(Q38215157)

31 August 2017

0 references

Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer (English)

1 reference

31 August 2017

1 reference

Bin Hu

1

1 reference

31 August 2017

Hongmei Yang

series ordinal

2

1 reference

31 August 2017

Hongwei Yang

series ordinal

3

1 reference

31 August 2017

publication date

27 May 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

35

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

8573-8580

1 reference

31 August 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

International variation in prostate cancer incidence and mortality rates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

The diagnostic odds ratio: a single indicator of test performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Meta-DiSc: a software for meta-analysis of test accuracy data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Rational approach to implementation of prostate cancer antigen 3 into clinical care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Prostate cancer: screening, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Active surveillance for early-stage prostate cancer: review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

PCA3: a molecular urine assay for predicting prostate biopsy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Cancer incidence and mortality in Europe, 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2109-4

Detecting Prostate Cancer with Molecular Markers: uPM3

21 January 2018

1 reference

12 December 2020

Transrectal ultrasound (TRUS) and TRUS-biopsy accuracy in potential candidates for PRIAS active surveillance protocol

1 reference

12 December 2020

The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients.

1 reference

12 December 2020

[Value of PCA3 urinary test for prostate biopsy decision: the Lyon-Sud University Hospital experience]

1 reference

12 December 2020

Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort

1 reference

12 December 2020

The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews

1 reference

12 December 2020

PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.

1 reference

12 December 2020

ROC Analysis Applied to the Evaluation of Medical Imaging Techniques

1 reference

12 December 2020

PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: our experience in 177 patients

1 reference

12 December 2020

10.1007/S13277-014-2109-4

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1050459117

0 references

1 reference